HUGE Rasio cepet FSD Pharma

FSD Pharma Inc. (HUGE) faces colossal market entry hurdles due to stringent FDA oversight and costly development processes. This chart of market trends in monetary terms shows that the liquidity ratio is 2.44. The company is currently developing cutting-edge treatments for depression and dementia through bioengineering; however, the lack of commercial products deprives the business of pricing power over therapy costs.

HUGE: Rasio jangkoan perantara FSD Pharma 04.07.2022 - 15.08.2024

Rincian analitis perusahaan FSD Pharma Inc.

- nilai pasar lan prakiraan target analis:

Bagan rega FSD Pharma Inc.|HUGE - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar FSD Pharma|HUGE - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi saben Saham FSD Pharma|HUGE - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku fsdpharma.com|HUGE - Total Aset Bisnis

- data utang lan likuiditas:

Total Utang marang Modal FSD Pharma Inc.|HUGE - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas FSD Pharma|HUGE - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku FSD Pharma|HUGE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan FSD Pharma|Likuiditas cepet fsdpharma.com

- informasi bathi lan kelipatan valuasi:

HUGE - Bathi resik perusahaan

Analisis wiwitan perusahaan:FSD Pharma Inc.

FSD Pharma Inc. (HUGE) is currently focusing on strict austerity and the divestment of non-core assets for survival. Under these conditions, the acid-test ratio demonstrates the company's ability to cover its liabilities using only cash and accounts receivable. This metric intentionally excludes inventories, which are difficult to convert into cash in the short term. This chart reflects the real financial stability of the business amid an acute liquidity shortage.

Karo sapa FSD Pharma Inc. saingan